✦ LIBER ✦

Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenoses With a Novel Platinum Chromium Thin-Strut Stent: Primary Results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) Trial

✍ Scribed by Dean J. Kereiakes; Louis A. Cannon; Robert L. Feldman; Jeffrey J. Popma; Raymond Magorien; Robert Whitbourn; Ira M. Dauber; Abram C. Rabinowitz; Michael W. Ball; Barry Bertolet; Ameer Kabour; Michael C. Foster; John C. Wang; Paul Underwood; Keith D. Dawkins

Book ID: 119269246
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 829 KB
Volume: 56
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2010.04.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TCT-240: PLATINUM QCA: A Prospective, Mu

TCT-240: PLATINUM QCA: A Prospective, Multicenter Trial Assessing Clinical, Angiographic, and Intravascular Ultrasound Outcomes (9 Months) with the Novel Platinum-Chromium Thin-Strut PROMUS Element Everolimus-Eluting Stent in De Novo Coronary Stenoses

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 115 KB

A Prospective, Randomized Evaluation of

A Prospective, Randomized Evaluation of a Novel Everolimus-Eluting Coronary Stent: The PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) Trial

✍ Gregg W. Stone; Paul S. Teirstein; Ian T. Meredith; Bruno Farah; Christophe L. D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 825 KB

A randomized, controlled, multi-center t

A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: Final results of the ZoMaxx II trial

✍ William A. Gray; Alan C. Yeung; Donald E. Cutlip; Jeffrey J. Popma; Peter J. Fit 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 382 KB

Comparison of Everolimus-Eluting and Pac

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials

✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 939 KB

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB

Long-Term Clinical and Economic Analysis

Long-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent: 4-Year Results From the ENDEAVOR II Trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions)

✍ Eric L. Eisenstein; William Wijns; Jean Fajadet; Laura Mauri; Rex Edwards; Patri 📂 Article 📅 2009 🏛 American College of Cardiology 🌐 English ⚖ 364 KB